Acrivon Therapeutics’ (ACRV) Market Outperform Rating Reiterated at Citizens Jmp

Citizens Jmp restated their market outperform rating on shares of Acrivon Therapeutics (NASDAQ:ACRV – Free Report) in a research report sent to investors on Tuesday,Benzinga reports.

Other analysts also recently issued research reports about the company. Wall Street Zen downgraded Acrivon Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, November 7th. Jefferies Financial Group reiterated a “buy” rating on shares of Acrivon Therapeutics in a report on Wednesday, November 11th. Finally, Weiss Ratings raised shares of Acrivon Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, October 9th. Four equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $13.50.

Check Out Our Latest Report on ACRV

Acrivon Therapeutics Price Performance

Shares of NASDAQ:ACRV opened at $1.40 on Tuesday. The company’s fifty day moving average price is $1.78 and its 200-day moving average price is $1.74. The firm has a market capitalization of $60.07 million, a price-to-earnings ratio of -0.77 and a beta of 1.96. Acrivon Therapeutics has a one year low of $1.27 and a one year high of $3.56.

Acrivon Therapeutics (NASDAQ:ACRV – Get Free Report) last posted its quarterly earnings data on Monday, November 16th. The company reported ($0.42) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.02. As a group, equities research analysts expect that Acrivon Therapeutics will post -1.69 EPS for the current year.

Insider Activity

In related news, CEO Peter Blume-Jensen sold 14,036 shares of the stock in a transaction dated Tuesday, August 25th. The shares were sold at an average price of $2.21, for a total transaction of $31,019.56. Following the sale, the chief executive officer directly owned 2,230,052 shares of the company’s stock, valued at approximately $4,928,414.92. This represents a 0.63% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders sold 17,444 shares of company stock valued at $36,320. 10.50% of the stock is owned by insiders.

Hedge Funds Weigh In On Acrivon Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Marshall Wace LLP boosted its position in Acrivon Therapeutics by 2.0% in the third quarter. Marshall Wace LLP now owns 542,344 shares of the company’s stock worth $1,112,000 after purchasing an additional 10,488 shares during the last quarter. Empowered Funds LLC bought a new stake in shares of Acrivon Therapeutics during the 3rd quarter valued at about $117,000. StoneX Group Inc. purchased a new stake in shares of Acrivon Therapeutics during the 3rd quarter valued at about $43,000. Spark Investment Management LLC purchased a new stake in shares of Acrivon Therapeutics during the 2nd quarter valued at about $50,000. Finally, Renaissance Technologies LLC increased its position in shares of Acrivon Therapeutics by 19.6% during the 1st quarter. Renaissance Technologies LLC now owns 758,440 shares of the company’s stock valued at $1,054,000 after purchasing an additional 124,271 shares during the last quarter. Institutional investors own 71.62% of the company’s stock.

About Acrivon Therapeutics

(Get Free Report)

Acrivon Therapeutics is a clinical-stage biopharmaceutical company developing precision medicines for cancer. Its research focuses on identifying treatments for patients whose tumors have molecular characteristics that may make them more likely to respond to a particular therapy. The company’s Acrivon Predictive Precision Proteomics (AP3) platform analyzes protein activity in tumor samples to identify these characteristics and help guide patient selection. Acrivon’s clinical-stage candidate ACR-368 is a small-molecule inhibitor of the CHK1 and CHK2 enzymes being studied in solid tumors.

Further Reading

Analyst Recommendations for Acrivon Therapeutics (NASDAQ:ACRV)

Receive News & Ratings for Acrivon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acrivon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.